Abstract  Macrophage autophagy has been shown to be protective against atherosclerosis. We previously discovered that ursolic acid (UA) promoted cancer cell autophagy. In the present study, we aimed to examine whether UA enhances macrophage autophagy in the context of atherogenesis. Cell culture study showed that UA enhanced autophagy of macrophages by increasing the expression of Atg5 and Atg16L1, which led to altered macrophage function. UA reduced pro-interleukin (IL)-1β protein levels and mature IL-1β secretion in macrophages in response to lipopolysaccharide (LPS), without reducing IL-1β mRNA expression. Confocal microscopy showed that in LPS-treated macrophages, UA increased LC3 protein levels and LC3 appeared to colocalize with IL-1β. In cholesterol-loaded macrophages, UA increased cholesterol efflux to apoA1, although it did not alter mRNA or protein levels of ABCA1 and ABCG1. Electron microscopy showed that UA induced lipophagy in acetylated LDL-loaded macrophages, which may result in increased cholesterol ester hydrolysis in autophagolysosomes and presentation of free cholesterol to the cell membrane. In LDLR−/− mice fed a Western diet to induce atherogenesis, UA treatment significantly reduced atherosclerotic lesion size, accompanied by increased macrophage autophagy. In conclusion, the data suggest that UA promotes macrophage autophagy and, thereby, suppresses IL-1β secretion, promotes cholesterol efflux, and attenuates atherosclerosis in mice.—Leng, S., S. Iwanowycz, F. Saaoud, J. Wang, Y. Wang, I. Sergin, B. Razani, and D. Fan. Ursolic acid enhances macrophage autophagy and attenuates atherogenesis. J. Lipid Res. 2016. 57: 1006–1016.

Supplementary key words  lipophagy • inflammation • cholesterol efflux • atherosclerosis

Autophagy is a highly conserved cellular response to stress, in which cellular components are self-consuming and recycled for downstream metabolism (1). Among the three major kinds of autophagy, macroautophagy, microautophagy, and chaperone-mediated autophagy, macroautophagy is the most prevalent form and, thus, commonly referred to as autophagy (2, 3). Over the past decade, research efforts regarding this ancient biological process have been revived due to the realization that alterations in autophagy play crucial pathological roles in many diseases (4, 5) for which current therapeutic means are limited. While many basic aspects of autophagy have been unraveled, little has been translated into clinical benefit, and no autophagy-modulating therapies have been approved for clinical use.

The autophagy process starts with the formation of a double-membrane autophagosome, which engulfs cytoplasmic materials. Autophagosomes are targeted to the lysosomal compartment and single-membrane autolysosomes are generated in which the sequestered cargos are degraded in the highly acidic environment and the resulting simple products are reused (6, 7). There are many molecules involved in autophagy, including Beclin-1 (involved in vesicle nucleation); Atg5, Atg7, and Atg16L1 (involved in vesicle elongation); and LC3 (involved in the expansion of autophagosome membrane and autophagosome-lysosome fusion) (8). Autophagy occurs in almost all cell types, including macrophages. Macrophages primarily use phagocytosis as the first line of defense against exogenous pathogens and endogenous waste products. They adopt autophagy to process bulky materials (e.g., damaged mitochondria and excessive lipids) in unfavorable microenvironments, thus mitigating cytotoxicity. Recently, autophagy has been shown to play a critical role in inflammatory responses in macrophages by interacting with inflammasomes or directly targeting pro-interleukin

Abbreviations: AcLDL, acetylated LDL; CE, cholesterol ester; FC, free cholesterol; IL, interleukin; LD, lipid droplet; LPS, lipopolysaccharide; ORO, Oil Red O; pMφ, peritoneal macrophage; qPCR, quantitative real-time PCR; TLR, toll-like receptor; UA, ursolic acid.

1 To whom correspondence should be addressed.
e-mail: shuilongleng@hotmail.com (S.L.); daping.fan@uscmed.sc.edu (D.F.)

The online version of this article (available at http://www.jlr.org) contains a supplement.
Ursolic acid (UA), a natural pentacyclic triterpene carboxylic acid found in various plants, is present in the human diet and possesses a wide range of biological functions, such as anti-oxidation, anti-inflammation (26), anti-cancer (27), and anti-hyperlipidemia (28). Some studies have reported that UA reduces obesity, glucose intolerance, and fatty liver (29, 30). These beneficial properties are of apparent value for the treatment of atherosclerosis, although the underlying molecular mechanisms are largely unknown. Indeed, limited but convincing studies have shown that macrophage autophagy is atheroprotective by substantially altering all these aspects, including the enhancement of cholesterol efflux, suppression of inflammation, and improvement of efferocytosis (11, 15, 23). Evidence showing that atherosclerosis progression is accompanied by increasing defects in macrophage autophagy provides further enthusiasm regarding the possibility that enhancement of macrophage autophagy may be an effective way to reduce or reverse atherosclerosis. However, currently known autophagy inducers, including mTOR inhibitors and toll-like receptor (TLR)7 ligands, are less than ideal therapeutics in the context of atherosclerosis, due to hyperlipidemic (24) and pro-inflammatory effects, respectively (25). Therefore, the search for new macrophage autophagy stimuli is urgent.

Materials and reagents

Ursolic acid (UA), a natural pentacyclic triterpene carboxylic acid found in various plants, is present in the human diet and possesses a wide range of biological functions, such as anti-oxidation, anti-inflammation (26), anti-cancer (27), and anti-hyperlipidemia (28). Some studies have reported that UA reduces obesity, glucose intolerance, and fatty liver (29, 30). These beneficial properties are of apparent value for the treatment of atherosclerosis, although the underlying molecular mechanisms are largely unknown. Indeed, limited but convincing studies have shown that macrophage autophagy is atheroprotective by substantially altering all these aspects, including the enhancement of cholesterol efflux, suppression of inflammation, and improvement of efferocytosis (11, 15, 23). Evidence showing that atherosclerosis progression is accompanied by increasing defects in macrophage autophagy provides further enthusiasm regarding the possibility that enhancement of macrophage autophagy may be an effective way to reduce or reverse atherosclerosis. However, currently known autophagy inducers, including mTOR inhibitors and toll-like receptor (TLR)7 ligands, are less than ideal therapeutics in the context of atherosclerosis, due to hyperlipidemic (24) and pro-inflammatory effects, respectively (25). Therefore, the search for new macrophage autophagy stimuli is urgent.

Materials and reagents

Ursolic acid (UA), a natural pentacyclic triterpene carboxylic acid found in various plants, is present in the human diet and possesses a wide range of biological functions, such as anti-oxidation, anti-inflammation (26), anti-cancer (27), and anti-hyperlipidemia (28). Some studies have reported that UA reduces obesity, glucose intolerance, and fatty liver (29, 30). These beneficial properties are of apparent value for the treatment of atherosclerosis, although the underlying molecular mechanisms are largely unknown. Indeed, limited but convincing studies have shown that macrophage autophagy is atheroprotective by substantially altering all these aspects, including the enhancement of cholesterol efflux, suppression of inflammation, and improvement of efferocytosis (11, 15, 23). Evidence showing that atherosclerosis progression is accompanied by increasing defects in macrophage autophagy provides further enthusiasm regarding the possibility that enhancement of macrophage autophagy may be an effective way to reduce or reverse atherosclerosis. However, currently known autophagy inducers, including mTOR inhibitors and toll-like receptor (TLR)7 ligands, are less than ideal therapeutics in the context of atherosclerosis, due to hyperlipidemic (24) and pro-inflammatory effects, respectively (25). Therefore, the search for new macrophage autophagy stimuli is urgent.

Cell culture and manipulation

RAW264.7 cells were obtained from ATCC (Rockville, MD) and were maintained in DMEM with 10% FBS. Thiglycollate-elicited mouse peritoneal macrophages (pMΦs) were obtained as previously described (33) and cultured in DMEM with 10% FBS for 2 h. Unattached cells were washed away, and the attached macrophages were then further cultured in appropriate medium. For LPS treatment, pMΦs were incubated for 6–24 h in the culture medium (DMEM with 0.25% FBS) with an addition of LPS and UA at the indicated concentrations. The cells were then washed with Dulbecco’s PBS twice before being lysed for total RNA or protein extraction. Raw 264.7 cells and pMΦs were treated with UA (10 μM) and TLR1/2 ligand Pam3CSK4 (500 ng/ml) or TLR4 ligand LPS (100 ng/ml) either alone or in combination, as indicated, for 6 h. In some experiments, cells were exposed to various autophagy modulators for 1 h prior to UA treatment, such as 500 nM Wortmannin to inhibit PI3K or 100 nM bafilomycin to inhibit degradation of LC3.

Mice

All mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed in the University of South Carolina Animal Research Facility. All animal experiments were carried out in compliance with the National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee of the University of South Carolina. In the serum IL-1β measurement experiment, C57BL/6 mice were randomly grouped (four mice in the control group, five mice in the LPS group, and five mice in LPS plus UA group) and were injected intraperitoneally with either LPS (20 μg/mouse) alone or together with UA (50 mg/kg), and blood was taken after 16 h for analysis of serum IL-1β by ELISA using kits from eBioscience (catalog number BMS6002INST; San Diego, CA). For atherosclerosis studies, female LDLR−/− mice were fed a Western diet and treated with UA for 11 weeks before they were euthanized for analysis. The Western diet contained 21% (wt/wt) anhydrous milkfat, 34% (wt/wt) sucrose, and a total of 0.2% (wt/wt) cholesterol (diet number TD.88137; Harlan Laboratories, Indianapolis, IN).

MTT assay

The pMΦs were cultured in phenol red-free medium in 24-well plates. Cytotoxicity of UA was determined using an MTT cell viability assay kit from ATCC Bioproducts™ (Manassas, VA) following the manufacturer’s instructions. The 96-well microplates were read using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA); absorbance at 570 nm was measured.
Macrophage cholesterol efflux

The cholesterol efflux assay was processed as previously described (34). Attached mouse macrophages in 24-well plates were cultured in DMEM for 24 h followed by cholesterol-loading with 100 μg/ml AcLDL incorporated with 3H-cholesterol for 3 days. Then efflux medium (either PBS-free DMEM or DMEM containing 20 μg/ml human apoAI or 50 μg/ml human HDL) with the absence or presence of 10 μM UA was added to initiate cholesterol efflux for 24 h. 3H-radioactivity in efflux medium and cells were counted using a Beckman LS6500 liquid scintillation counter (Beckman Coulter, Indianapolis, IN). Cholesterol efflux rate was calculated as the percentage of the radioactive counts in the medium.

Quantitative real-time PCR

Total RNA was extracted using TRIzol reagent (Invitrogen, San Diego, CA) and reverse transcribed into cDNA using iScript™ Reverse Transcription Supermix (Bio-Rad Laboratories, Inc., Hercules, CA). Quantitative real-time PCR (qPCR) analysis was carried out using iQ™ SYBR® Green Supermix (Bio-Rad) on an Eppendorf Realplex2 mastercycler (Eppendorf, Hamburg, Germany). The primers used in qPCR were: mouse 18S RNA (internal control), 5′-CAGCTGCCATTCTTTTGGTTG-3′ (forward) and 5′-AGTCGGCATGTATTTTAGCTG-3′ (reverse); mouse IL-1β, 5′-GGGCTCCCTCTGCAGCTAC-3′ (forward) and 5′-AGGAGCA- GATTTTCTTGC-3′ (reverse); mouse Becn1, 5′-GGCCCTTAAAGATGCTGTCA-3′ (forward) and 5′-GCTGCAACAGTCAGAAA-3′ (reverse); mouse Atg16L1, 5′-GGTGGCCCTAGGTTTGTGAG-3′ (forward) and 5′-ACCTGGCTCCAGGAGAC-3′ (reverse); mouse Atg4c, 5′-GCCATTCTCTTTCTCAAAGA-3′ (forward) and 5′-AAAACCCGGAAGTCCTCAGT-3′ (reverse); mouse Atg5, 5′-AGATGAGAAGTGTCAGCAGC-3′ (forward) and 5′-GCTGGGAGAACATGCTATA-3′ (reverse). Samples were amplified using the following program: 95°C for 10 min followed by 40 cycles of 95°C for 10 s, 60°C for 15 s, and 72°C for 20 s, and then a melting curve analysis from 60 to 95°C every 0.2°C. The abundance of each gene product was calculated by relative quantification, with values for the target genes normalized with 18S RNA.

Western blot

Protein samples were loaded onto SDS-PAGE gels for electrophoresis. The size-separated proteins were then transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ). The indicated primary antibodies and HRP-conjugated secondary antibodies were used to detect target proteins. Signal was detected using an ECL kit (Bio-Rad). For stripping, membranes were submerged for 30 min at 55–60°C in a buffer containing 100 mM 2-mercaptoethanol, 2% (v/v) SDS and 62.5 mM Tris-HCl (pH 6.7), with agitation, and then were washed three times with PBS.

Measurement of cytokines in cell culture medium or serum

Cytokine protein concentrations in cell culture medium or serum were measured by ELISA, using kits from eBioscience (San Diego, CA) following the manufacturer’s instructions. The macrophage-conditioned culture medium was diluted by 30- to 180-fold for the measurement. The 96-well microplates were read using a SpectraMax M5 microplate reader and permeabilized for 10 min with Triton X-100 (0.1% in PBS). All subsequent steps were conducted at room temperature. The cells were blocked with 0.01 M glycine/PBS three times, 30 min each time, and then with 5% BSA in PBS for 1 h and stained with primary antibody (rabbit anti-LEC5 or goat anti-IL-1B at 1:200 in blocking buffer) for 1 h. After washing three times with PBS, the cells were stained with Alexa Fluor 555-conjugated goat anti-rabbit IgG (1:500 in PBS) and with Alexa Fluor 488-conjugated donkey anti-goat IgG (1:500 in PBS) for 1 h. The cells were stained with 4′,6-diamidino-2-phenylindole (5 μg/ml) for 5 min and then washed with PBS. The coverslips were mounted onto glass slides with fluorescent mounting medium (Dabco) and analyzed on an Olympus FV1000 laser scanning confocal microscope (Tokyo, Japan).

Transmission electron microscopy

Cells were cultured on Permanox four chamber slides for different lengths of time. Cells were fixed with 1 – 2% glutaraldehyde for 30 min and then rinsed with PBS three times; they were then incubated in 1% osmium tetroxide with 1.5% potassium ferricyanide for 30 min and then rinsed with water. The cells were dehydrated by incubating them in 70% ethanol for 15 min twice, then 95% ethanol for 15 min twice, and finally 100% ethanol for 20 min. The cells were then incubated in ethanol and acetonitrile (1:1) for 10 min, then with acetonitrile for 10 min twice; next they were incubated in PolyBed 812 and acetonitrile (1:2) for 1 h, then with PolyBed 812 and acetonitrile (2:1) for 1 h, and within pure PolyBed 812 overnight. Cells were embedded in mold 48 h at 60°C, which was examined by transmission electron microscopy; 50 cells in each group were examined.

Cellular cholesterol analysis

The intracellular total cholesterol and FC were measured by an intracellular cholesterol quantitation kit (Sigma-Aldrich) according to the manufacturer’s instructions. Briefly, macrophages were trypsinized with trypsin-EDTA followed by centrifugation. The cell pellets were resuspended in a mix of chloroform/isopropanol:3GEPAL CA-630 (7:11:0.1). The samples were centrifuged at 13,000 g for 10 min to remove insoluble material. The organic phase was transferred to new tubes and air dried at 50°C for 30 min, followed by blowing the samples with nitrogen to remove organic solvent. The lipid was dissolved with 200 μl cholesterol assay buffer; 50 μl of the reaction mix was added to each standard and sample well in a 96-well plate and incubated for 60 min at 37°C in the dark. The absorbance at OD 570 nm was measured with a Spectra Max M5 microplate reader (Molecular Devices).

Plasma lipid analysis

Blood was obtained from mice following an overnight fast and the plasma was obtained by centrifugation of the blood at 4,000 g for 20 min. Plasma cholesterol and triglyceride levels were measured by enzymatic colorimetric assays with cholesterol reagent and triglycerides GPO reagent kits (Raichem, SanDiego, CA). Plasma cholesterol lipoprotein profiles were determined using a fast-performance LC system (AKTA purifier, GE Healthcare Biosciences, Pittsburgh, PA) equipped with a Superox 6 10/300 GL column (GE Healthcare). Pooled mouse plasma (100 μl) was loaded onto the column and eluted at a constant flow rate of 0.5 ml/min with 1 mM sodium EDTA and 0.15 M NaCl. Fractions of 0.5 ml were collected and cholesterol concentration from each fraction was measured.

Atherosclerosis analysis

Hearts and aortas were dissected from mice and processed as described previously (35). The base of the heart containing the
Statistical analysis

All data were summarized as mean ± SEM. To compare two groups on a continuous response variable (e.g., gene expression levels and atherosclerosis size), we used a t-test. To compare multiple groups on a continuous response variable, we used a one-way ANOVA followed by Bonferroni post assay to compare the selected two groups. Normality and homoscedasticity were tested to ensure that parametric testing was appropriate. P < 0.05 was considered statistically significant. GraphPad Prism 5 software was used to carry out all statistical analysis.

RESULTS

UA enhances macrophage autophagy

The structure of UA was confirmed by NMR; the purity was determined by mass spectroscopy and HPLC to be >98% (data not shown). Its cytotoxicity was measured by MTT assay. UA was dissolved in DMSO as a stock solution of 10 mM and then diluted into appropriate media. Mouse pMΦs and Raw264.7 cells were treated with 0–40 μM UA for up to 5 days. Data showed that at concentrations up to 10 μM, UA did not cause any apparent cytotoxicity to both cell types, but it led to cell death at >30 μM (data not shown). Therefore, we used UA at 10 μM or lower for all the following experiments. To examine whether UA increases macrophage autophagy, we treated mouse pMΦs with UA and Wortmannin (an autophagy inhibitor). UA-enhanced autophagy was evidenced by increased LC3-I/II proteins, whereas Wortmannin completely blocked UA-induced LC3 increase (Fig. 1A). Next, using Raw264.7 cells, we confirmed UA’s autophagy-inducing activity. Data showed that UA at 10 μM was 2-fold more effective in increasing LC3I/II expression than rapamycin at 100 nM (Fig. 1B).

The autophagy-enhancing effect of UA was also evident as observed by electron microscopy. As shown in Fig. 1C, UA-treated pMΦs had numerous double-membrane structures that were characteristic of nascent autophagosomes, autophagosomes, and autolysosomes, while much fewer of these structures were detected in control cells. Autophagosomes and nascent autophagosomes could not be clearly distinguished in the micrographs. The structure indicated as “autophagosomes” could also be nascent autophagosomes. In autolysosomes, the segregated organelles lose their distinct shape and are usually replaced by electron-dense materials. The diameter of typical autophagosomes or autolysosomes is 0.5–2 μm. These electron microscopy data have confirmed that UA induces autophagy in pMΦs.

To examine the mechanisms by which UA enhances macrophage autophagy, qPCR was performed and showed that in both mouse pMΦs and Raw264.7 cells, UA at 10 μM significantly increased the expression of autophagy-related proteins Atg5 and Atg16L1, but not that of Atg4c and Beclin-1 (BECN1) (Fig. 1D, E). UA did not change LC3 mRNA expression in macrophages either (data not shown).

UA suppresses IL-1β production in macrophages

It has been reported that UA has anti-inflammatory effects on macrophages (26). To investigate the effects of UA on pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα, pMΦs were treated with LPS (100 ng/ml) and/or UA (10 μM) for 6 h, and the expression of the abovementioned cytokines was examined using qPCR. As shown in Fig. 2A and supplementary Fig. 1A, LPS significantly increased the mRNA expression of IL-1β, IL-6, and TNFα; UA only slightly (without statistical significance) suppressed LPS-induced expression of these cytokines. However, Western blot analysis showed that UA substantially reduced the pro-IL-1β protein level in both LPS-treated pMΦs and Raw264.7 cells (Fig. 2B).

We next examined whether UA suppresses mature IL-1β secretion. Mouse pMΦs were treated with LPS or Pam3CSK4 with or without UA for 16 h and the conditioned medium was collected for ELISA measurement of IL-1β protein levels. The result showed that LPS and Pam3CSK4 stimulated the secretion of IL-1β, whereas UA significantly inhibited the secretion of IL-1β (Fig. 2C). However, UA did not significantly reduce the secretion of IL-6 or TNFα in LPS-treated mouse pMΦs (supplementary Fig. 1B).

To determine whether UA suppresses IL-1β production in vivo, we injected C57BL/6 mice intraperitoneally with either PBS (control), LPS alone, or LPS together with UA (50 mg/kg). Sixteen hours after injection, blood samples were taken for analysis of serum IL-1β concentration by ELISA. The results showed that LPS significantly increased serum IL-1β levels and UA significantly suppressed the induction (Fig. 2D). We developed a method to measure mouse serum UA concentration by coupling HPLC.
The overlap between IL-1β and LC3 signals indicates that autophagy induced by UA may sequester pro-IL-1β in autophagic vesicles.

UA promotes cholesterol efflux from lipid-loaded macrophages

Autophagy has been shown to enhance cholesterol efflux to apoAI (12–14). To examine whether UA promotes macrophage cholesterol efflux by enhancing autophagy, we used mouse pMΦs to perform experiments using previously established protocol (35). We found that UA (10 μM) significantly increased cholesterol efflux to apoAI, but not to HDL (Fig. 3A). An autophagic flux inhibitor, bafilomycin A1, completely diminished the cholesterol efflux enhancement by UA (Fig. 3B). qPCR and Western blots showed that UA did not increase the mRNA expression and protein levels of ABCA1 and ABCG1 (Fig. 3C, D), indicating that the cholesterol efflux enhancing effects of UA are not caused by ABCA1 or ABCG1 induction.

To search for evidence of autophagic vacuoles in lipid-loaded macrophages and, if present, whether these were associated with lipid droplets (LDs), electron microscopic analysis was performed. The results clearly showed that UA increased lipophagy in AcLDL-loaded macrophages (Fig. 3E). LDs were easily identifiable as round light-density structures in AcLDL-loaded cells [Fig. 3E(b), white
Ursolic acid enhances macrophage autophagy

Female LDLR\(^{-/-}\) mice at an age of 8 weeks were randomly divided into two groups (9–10 mice per group) and fed a Western diet for 11 weeks. In the DMSO group, the mice were injected intraperitoneally with vehicle (0.1% DMSO in 1 ml PBS) every other day; while in the UA group, the mice were injected with UA (50 mg/kg in 1 ml PBS with 0.1% DMSO) every other day. Food intake and body weight were measured weekly. We noticed that, while the food intake was not different between the two groups (supplementary Fig. 2A), the body weights of the UA group mice were lower than the vehicle group in the first 3 weeks after the initiation of Western diet and UA treatment, but they caught up in the following weeks; at the endpoint, body weights of the two groups were not significantly different (supplementary Fig. 2B). The mice were euthanized and comprehensive analyses were performed to compare the two groups. We did not find any significant differences between the two groups of mice in total serum cholesterol (supplementary Fig. 2C), triglycerides (supplementary Fig. 2D), and fasting blood glucose (supplementary Fig. 2E).

To examine whether UA increases cholesterol ester (CE) hydrolysis through enhancing autophagy, we measured total cholesterol and FC in mouse pM\(\Phi\)s loaded with 50 \(\mu\)g/ml AcLDL in the absence or presence of 10 \(\mu\)M UA in serum-free DMEM for 24 h; and the CE and FC/CE ratio were calculated. We found that, while UA did not significantly reduce total cholesterol loading to the macrophages, it significantly increased the FC/CE ratio (Fig. 3F), indicating that UA, indeed, increased CE hydrolysis in macrophages.

**UA attenuates atherogenesis in hypercholesterolemic mice**

Because UA was shown to suppress macrophage IL-1\(\beta\) production and secretion and enhance macrophage cholesterol efflux, we next examined whether UA treatment could reduce atherosclerosis in mouse models. Female LDLR\(^{-/-}\) mice at an age of 8 weeks were randomly divided into two groups (9–10 mice per group) and fed a Western diet for 11 weeks. In the DMSO group, the mice were injected intraperitoneally with vehicle (0.1% DMSO in 1 ml PBS) every other day; while in the UA group, the mice were injected with UA (50 mg/kg in 1 ml PBS with 0.1% DMSO) every other day. Food intake and body weight were measured weekly. We noticed that, while the food intake was not different between the two groups (supplementary Fig. 2A), the body weights of the UA group mice were lower than the vehicle group in the first 3 weeks after the initiation of Western diet and UA treatment, but they caught up in the following weeks; at the endpoint, body weights of the two groups were not significantly different (supplementary Fig. 2B). The mice were euthanized and comprehensive analyses were performed to compare the two groups. We did not find any significant differences between the two groups of mice in total serum cholesterol (supplementary Fig. 2C), triglycerides (supplementary Fig. 2D), and fasting blood glucose (supplementary Fig. 2E),
significance (Fig. 4C). However, the collagen content (percentage) in the lesions, as determined by Movat’s pentachrome staining, was significantly larger in the UA group (22.9 ± 2.0%) than in the vehicle group (14.7 ± 2.6%) (Fig. 4D). Furthermore, the atherosclerotic lesion area in en face aortas was significantly smaller in the UA group than in the vehicle group (supplementary Fig. 3B, C).

We also stained IL-1β and LC-3 in the aortic root slides to examine whether UA induced autophagy and reduced IL-1β in atherosclerotic lesions. The autophagy levels (reflected by LC-3 staining) in atherosclerotic lesions were increased in the UA group compared with the control group, especially in the macrophage-rich lesions. Meanwhile, the positivity of IL-1β was significantly decreased in the atherosclerotic lesions of the UA group compared with the control group. More interestingly, in the lesions of the UA group, there was significantly more IL-1β and LC-3 overlapping (Fig. 5). Our results suggested that UA treatment has increased autophagy in the atherosclerotic lesion, as well as pro-IL-1β degradation in the autophagosome.

DISCUSSION

In this study, we demonstrate that a phytonutrient, UA, enhances macrophage autophagy, suppresses macrophage...
IL-5 levels in the mice. B: The lipid content in lesions was determined but did not significantly alter serum IL-1β levels, and protein levels of LC3II; electron microscopy confirmed that UA increases autophagosome formation in macrophages. However, the more detailed molecular mechanisms warrant further investigation; for example, what targets UA directly binds to in the cell or on the cell membrane, and how UA modulates Atg5 and Atg16l1 expression, but not several other autophagy-related genes.

Macrophages contribute to atherogenesis by serving as inflammatory machinery and as a lipid deposit tank. Autophagy has been shown to reduce macrophage inflammation and foam cell formation by various mechanisms. In the arm of inflammation in the arterial intima, oxidized lipids and other inflammatory stimuli provoke macrophages to produce a variety of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, among which IL-1β plays a dominant role in the inflammatory cascade in the plaques. In this study, we show that UA significantly reduced intracellular pro-IL-1β levels and mature IL-1β secretion in LPS-treated macrophages, although it did not reduce IL-1β mRNA expression. Increasing evidence suggests that autophagy is necessary to keep down the endogenous sources of inflammasome and IL-1β activation (36). Macrophages derived from Atg16l1-deficient mice produced higher levels of IL-1β (9). Additional studies using cells of human origin demonstrated that the inhibition of autophagy led to the upregulated production of IL-1β (37, 38). To examine how UA regulates IL-1β production in macrophages, we used immunofluorescence confocal microscopy to observe colocalization of IL-1β and LC3 in Raw 264.7 cells after treatment by TLR ligands combined with UA. The overlap between IL-1β and LC3 indicated that autophagy induced by UA brought pro-IL-1β into the lumen of autophagic vacuoles for degradation, thereby reducing pro-IL-1β in the cells, which was usually processed by caspase 1 to generate mature IL-1β for secretion; although UA-induced autophagy did not suppress active caspase 1 generation through inflammasomes.

Oxidized or other modified LDL, unlike normal LDL, is readily taken up by the macrophage through scavenger receptors SR-A or CD36, resulting in the formation of macrophage foam cells. Accumulation of lipid-loaded macrophage foam cells is a central feature in the formation of atherosclerotic plaques (39, 40). Maintaining macrophage cholesterol homeostasis is essential for the prevention and treatment of atherosclerosis. In this study, we provide evidence that UA enhanced apoAI-mediated cholesterol efflux from macrophage foam cells through autophagy. Our data show that UA enhanced apoAI-mediated cholesterol efflux, which can be blocked by the autophagic flux inhibitor, bafilomycin A1.

IL-1β secretion, and promotes cholesterol efflux from cholesterol-loaded macrophages. Furthermore, we show that administration of UA attenuates atherogenesis in hyperlipidemic mouse models. This represents the first report that a natural compound suppresses atherosclerosis through a mechanism that is associated with macrophage autophagy enhancement.

Several recent studies have convincingly shown that macrophage autophagy plays a protective role against atherogenesis in mouse models. However, using macrophage autophagy induction as an anti-atherogenic strategy is a distant goal because none of the known autophagy inducers or enhancers have been shown to be beneficial without reasonable side effects in preclinical studies. For example, systemic administration of mTOR inhibitors at levels sufficient for autophagy induction in macrophages causes systemic immunosuppression. The characterization of UA as a macrophage autophagy inducer in this study may add this natural compound as a new compound for clinical development toward a new anti-atherogenic agent. We show that UA enhances macrophage autophagy by increasing mRNA expression of Atg5 and Atg16l1 and protein levels of LC3II; electron microscopy confirmed that UA increases autophagosome formation in macrophages. However, the more detailed molecular mechanisms warrant further investigation; for example, what targets UA directly binds to in the cell or on the cell membrane, and how UA modulates Atg5 and Atg16l1 expression, but not several other autophagy-related genes.

Macrophages contribute to atherogenesis by serving as inflammatory machinery and as a lipid deposit tank. Autophagy has been shown to reduce macrophage inflammation and foam cell formation by various mechanisms. In the arm of inflammation in the arterial intima, oxidized lipids and other inflammatory stimuli provoke macrophages to produce a variety of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, among which IL-1β plays a dominant role in the inflammatory cascade in the plaques. In this study, we show that UA significantly reduced intracellular pro-IL-1β levels and mature IL-1β secretion in LPS-treated macrophages, although it did not reduce IL-1β mRNA expression. Increasing evidence suggests that autophagy is necessary to keep down the endogenous sources of inflammasome and IL-1β activation (36). Macrophages derived from Atg16l1-deficient mice produced higher levels of IL-1β (9). Additional studies using cells of human origin demonstrated that the inhibition of autophagy led to the upregulated production of IL-1β (37, 38). To examine how UA regulates IL-1β production in macrophages, we used immunofluorescence confocal microscopy to observe colocalization of IL-1β and LC3 in Raw 264.7 cells after treatment by TLR ligands combined with UA. The overlap between IL-1β and LC3 indicated that autophagy induced by UA brought pro-IL-1β into the lumen of autophagic vacuoles for degradation, thereby reducing pro-IL-1β in the cells, which was usually processed by caspase 1 to generate mature IL-1β for secretion; although UA-induced autophagy did not suppress active caspase 1 generation through inflammasomes.

Oxidized or other modified LDL, unlike normal LDL, is readily taken up by the macrophage through scavenger receptors SR-A or CD36, resulting in the formation of macrophage foam cells. Accumulation of lipid-loaded macrophage foam cells is a central feature in the formation of atherosclerotic plaques (39, 40). Maintaining macrophage cholesterol homeostasis is essential for the prevention and treatment of atherosclerosis. In this study, we provide evidence that UA enhanced apoAI-mediated cholesterol efflux from macrophage foam cells through autophagy. Our data show that UA enhanced apoAI-mediated cholesterol efflux, which can be blocked by the autophagic flux inhibitor, bafilomycin A1.
By doing so, UA did not increase ABCA1 and ABCG1 expression; instead, UA increased lipophagy in macrophages, evidenced by the fusion of autophagosomes with LDs in the electron microscopic images. Our finding that enhanced autophagy is associated with improved cholesterol efflux from macrophages is consistent with previous reports (13, 14). It is worth noting that our electron microscopic images show that UA increased the frequency of LDs with areas of high density and asymmetrically localized multi-membrane structures. For larger LDs, autophagosomes only engulfed a discrete part of the LDs, which then pinched off as membrane vesicles enriched in LC3 (autolipophagosomes), in this way autophagosomes occur on the surface of these large organelles. Such partial engulfment of organelles by autophagy has been described for the nucleus and endoplasmic reticulum (41, 42).

We further demonstrate that the beneficial effects of UA on macrophage inflammatory response and cholesterol homeostasis translate well into atherosclerosis reduction in mouse models. We show that peritoneal injection of UA at 50 mg/kg once every other day in LDLR−/− mice fed a Western diet for 11 weeks significantly reduced atherosclerotic plaque formation. Detailed composition analysis for LDLR−/− mice showed that UA reduced the overall lesion size, the lipid containing area, and the macrophage content, while it increased the collagen content, suggesting that UA treatment results in smaller and more stable lesions in mice. Further immunohistochemical analysis revealed that UA treatment reduced IL-1β levels, but increased LC3 levels, in atherosclerotic plaque, and that UA significantly increased the colocalization of IL-1β and LC3 in the lesions, indicating that UA, indeed, reduced IL-1β concentration in plaque through enhancing autophagy and IL-1β sequestration and degradation in the autophagic pathway. ELISA data further confirmed the reduction of IL-1β in serum. These in vivo data demonstrate that the macrophage autophagy-inducing effects indeed confer UA with anti-atherogenic capacity.

There are two previous studies that investigated the effects of UA on atherosclerosis using mouse models that obtained opposite results. Ullevig et al. (31) showed that UA has anti-atherogenic effects on female LDLR−/− mice induced to be diabetic and fed a high fat diet supplemented with UA for 11 weeks. The mechanism was suggested to be monocyte recruitment suppression. Our results are in agreement with these findings because the absolute MOMA-2-stained area in the plaques of our LDLR−/− mice was reduced, although the area percentage reduction did not reach statistical significance. On the other hand, Messner et al. (43) reported a UA dose-dependent increase in atherosclerosis in Western diet-fed male apoE−/− mice receiving UA in drinking water for 24 weeks. The mechanisms were proposed to be endothelial cell death induction and serum IL-5 reduction caused by UA consumption. In our study, we did not examine the endothelial proliferation and apoptosis in UA-treated mice, but did not observe a significant decrease of serum IL-5 levels in LDLR−/− mice. As correctly pointed out by Tannock (44), all these studies, including ours, were designed differently, including the animal model, the UA administration route, the dose, and the duration, and the mechanistic studies evaluated different cell types. In our study, we administered UA using peritoneal injection, avoiding the potential metabolism of UA in the gut and first pass effects in the liver. The plasma UA concentration determined in mice was 3–12 μM within 24 h after a single injection, which is close to the concentrations we used in the in vitro macrophage experiments, indicating that the macrophage autophagy-enhancing mechanism identified in in vitro experiments can at least partially explain the anti-atherogenic effects. Indeed, we also directly observed enhanced autophagy in the plaques of UA-treated mice. Nevertheless, more studies are needed to confirm the effects of UA on atherosclerosis and to more comprehensively examine the mechanisms.

In conclusion, our data suggest that UA enhances macrophage autophagy and thus reduces pro-IL-1β processing into mature IL-1β, and promotes macrophage cholesterol efflux (as depicted in Fig. 6). Both of these effects are anti-atherogenic, contributing to the attenuated atherogenesis in LDLR−/− mice fed a Western diet. Our study provides evidence that UA might be an optimal anti-atherogenic therapy by virtue of its macrophage autophagy-enhancing activity.
IL-1α for secretion. Autophagosomes also interact with LDs, encircling some lipids to form autophagophagosomes, then fuse with autolysosomes to form an autolysosome, which processes the containing lipids and presents FC to the cell membrane for ABCA1-mediated cholesterol efflux.

Fig. 6. Schematic depiction of the effects of UA on macrophages. UA enhances autophagy in macrophages by increasing expression of autophagy-related proteins Atg5 and Atg16L1. Autophagosome sequesters pro-IL-1β and leads to pro-IL-1β degradation in lysosomes, diverting it from being processed by caspase 1 into mature IL-1β for secretion. Autophagosomes also interact with LDs, encircling some lipids to form autolipophagosomes, and then fuse with autolysosomes to form an autolysosome, which processes the containing lipids and presents FC to the cell membrane for ABCA1-mediated cholesterol efflux.

REFERENCES

1. Kundu, M., and C. B. Thompson. 2008. Autophagy: basic principles and relevance to disease. Annu. Rev. Pathol. 3: 427–455.
2. Yang, Z., and D. J. Klionsky. 2010. Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22: 124–131.
3. Bova, P., F. Reggiori, and P. Codogno. 2013. Emerging regulation and functions of autophagy. Nat. Cell Biol. 15: 713–720.
4. Martinet, W., A. Agostinis, B. Vanhoecke, M. Dewaele, and G. R. Agostinis. 2007. Molecular machinery and signaling regulation. Mol. Nutr. Food Res. 52: 26–42.
5. Saitoh, T., N. Fujita, M. H. Jang, S. Uematsu, B. G. Yang, T. Satoh, J. J. Lee, T. Asashima, H. S. Kruth. 2008. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 28: 243–248.
6. Swirski, F. K., R. Weisfleder, and M. J. Pittet. 2009. Heterogeneity in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29: 1424–1432.
7. Tabas, I. 2010. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10: 36–46.
8. Tschopp, J., and P. Ting. 2012. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab. 545–553.
9. Waldo, S. W., Y. Li, C. Buono, B. Zhao, E. M. Billings, J. Chang, and H. S. Kruth. 2008. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 28: 1112–1126.
10. Shimada, K. 2009. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Curr. J. 73: 994–1001.
11. Waldo, S. W., Y. Li, C. Buono, B. Zhao, E. M. Billings, J. Chang, and H. S. Kruth. 2008. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 28: 1112–1126.
12. Swirski, F. K., R. Weisfleder, and M. J. Pittet. 2009. Heterogeneity in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29: 1424–1432.
13. Bonilla, D. L., A. Bhattacharya, Y. Sha, Y. Xu, Q. Xiang, A. Kan, C. Jagannath, M. Komatsu, and N. T. Eissa. 2013. Autophagy regulates phagocytosis by modulating the expression of scavenger receptors. Immunity, 39: 537–547.
14. Shashkin, P., B. Dragulev, and K. Levy. 2005. Macrophage differentiation to foam cells. Curr. Pharm. Des. 11: 3061–3072.
15. Liao, X., J. C. Sluimer, Y. Wang, M. Subramanian, K. Brown, J. S. Patterson, J. Robbins, J. Martinez, and I. Tabas. 2012. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 15: 545–553.
16. Bonilla, D. L., A. Bhattacharya, Y. Sha, Y. Xu, Q. Xiang, A. Kan, C. Jagannath, M. Komatsu, and N. T. Eissa. 2013. Autophagy regulates phagocytosis by modulating the expression of scavenger receptors. Immunity, 39: 537–547.
17. Hansson, G. K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6: 508–519.
18. Ouimet, M., and Y. L. Marcel. 2012. Regulation of lipid droplet containing lipids and presents FC to the cell membrane for ABCA1-mediated cholesterol efflux.

Ursolic acid enhances macrophage autophagy

1015
37. Shin, S. W., S. Y. Kim, and J. W. Park. 2012. Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells. *Biochim. Biophys. Acta.* 1823: 451–457.

38. Plantinga, T. S., T. O. Crisan, M. Oosting, F. L. van de Veerdonk, D. J. de Jong, D. J. Philpott, J. W. van der Meer, S. E. Girardin, L. A. Joosten, and M. G. Netea. 2011. Crohn’s disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. *Gut.* 60: 1229–1235.

39. Moore, K. J., and I. Tabas. 2011. Macrophages in the pathogenesis of atherosclerosis. *Cell.* 145: 341–355.

40. Moore, K. J., F. J. Sheedy, and E. A. Fisher. 2013. Macrophages in atherosclerosis: a dynamic balance. *Nat. Rev. Immunol.* 13: 709–721.

41. Roberts, P., S. Moshitch-Moshkovitz, E. Kvam, E. O’Toole, M. Winey, and D. S. Goldfarb. 2003. Piecemeal microautophagy of nucleus in Saccharomyces cerevisiae. *Mol. Biol. Cell.* 14: 129–141.

42. Bernales, S., K. L. McDonald, and P. Walter. 2006. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. *PLoS Biol.* 4: e423.

43. Messner, B., I. Zeller, C. Ploner, S. Frotschnig, T. Ringer, A. Steinacher-Nigisch, A. Ritsch, G. Laufer, C. Huck, and D. Bernhard. 2011. Ursolic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. *Atherosclerosis.* 219: 402–408.

44. Tannock, L. R. 2011. Ursolic acid effect on atherosclerosis: apples and apples, or apples and oranges? *Atherosclerosis.* 219: 397–398.